DK0765327T3 - Pyrazolo- og pyrrolopyridiner - Google Patents

Pyrazolo- og pyrrolopyridiner

Info

Publication number
DK0765327T3
DK0765327T3 DK95917436T DK95917436T DK0765327T3 DK 0765327 T3 DK0765327 T3 DK 0765327T3 DK 95917436 T DK95917436 T DK 95917436T DK 95917436 T DK95917436 T DK 95917436T DK 0765327 T3 DK0765327 T3 DK 0765327T3
Authority
DK
Denmark
Prior art keywords
pyrrolopyridines
pyrazolo
formulawherein
stress
compounds
Prior art date
Application number
DK95917436T
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0765327T3 publication Critical patent/DK0765327T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Controls And Circuits For Display Device (AREA)
  • Projection Apparatus (AREA)
DK95917436T 1994-06-16 1995-05-18 Pyrazolo- og pyrrolopyridiner DK0765327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26005594A 1994-06-16 1994-06-16
PCT/IB1995/000373 WO1995034563A1 (en) 1994-06-16 1995-05-18 Pyrazolo and pyrrolopyridines

Publications (1)

Publication Number Publication Date
DK0765327T3 true DK0765327T3 (da) 1999-11-29

Family

ID=22987613

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95917436T DK0765327T3 (da) 1994-06-16 1995-05-18 Pyrazolo- og pyrrolopyridiner

Country Status (27)

Country Link
US (1) US6248753B1 (da)
EP (1) EP0765327B1 (da)
JP (1) JP2891544B2 (da)
KR (1) KR100235277B1 (da)
CN (1) CN1056611C (da)
AT (1) ATE182332T1 (da)
AU (1) AU687196B2 (da)
BR (1) BR9502707A (da)
CA (1) CA2192820C (da)
CO (1) CO4290424A1 (da)
CZ (1) CZ287613B6 (da)
DE (1) DE69510940T2 (da)
DK (1) DK0765327T3 (da)
ES (1) ES2135062T3 (da)
FI (1) FI112659B (da)
GR (1) GR3031166T3 (da)
HU (1) HU219911B (da)
IL (1) IL114003A (da)
MX (1) MX9606504A (da)
NO (1) NO307968B1 (da)
NZ (1) NZ284846A (da)
PE (1) PE13396A1 (da)
PL (1) PL181895B1 (da)
RU (1) RU2135498C1 (da)
TW (1) TW432064B (da)
WO (1) WO1995034563A1 (da)
ZA (1) ZA954679B (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
WO1997035846A1 (en) * 1996-03-26 1997-10-02 Dupont Pharmaceuticals Company Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
ZA972497B (en) 1996-03-27 1998-09-25 Du Pont Merck Pharma Arylamino fused pyridines and pyrimidines
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
EA003188B1 (ru) * 1996-08-06 2003-02-27 Пфайзер Инк Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
JP2001511813A (ja) 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
AU746706B2 (en) * 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
WO1999011643A1 (en) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6310063B1 (en) 1998-04-02 2001-10-30 Neurogen Corporation Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
CA2326319A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
DE19837387A1 (de) * 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
JP2002529469A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
PT1129091E (pt) * 1998-11-12 2003-02-28 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos relacionados
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
AU3264201A (en) 1999-12-17 2001-06-25 Du Pont Pharmaceuticals Company Imidazopyrimidinyl and imidazopyridinyl derivatives
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
ATE287886T1 (de) 2000-04-25 2005-02-15 Bristol Myers Squibb Co Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
DE10042093A1 (de) * 2000-08-26 2002-03-07 Dresden Arzneimittel Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung
AU2002213929B2 (en) 2000-09-22 2006-04-13 Merck Sharp & Dohme B.V. Bicyclic heteroaromatic compounds
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
RU2296753C2 (ru) * 2001-02-22 2007-04-10 Селлтек Р Энд Д Лимитед Производные 3-оксо-1-циклобутена и фармацевтическая композиция на их основе
US6562867B2 (en) * 2001-02-27 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
CN1290846C (zh) 2001-04-27 2006-12-20 卫材株式会社 吡唑并[1,5－a]吡啶化合物及其药物
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
WO2003030904A1 (en) * 2001-10-08 2003-04-17 F. Hoffmann-La Roche Ag 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
DE60213851T2 (de) * 2001-12-04 2007-09-13 F. Hoffmann-La Roche Ag Ringannelierte pyrazolderivate
DE60331219D1 (de) * 2002-03-28 2010-03-25 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
RU2357967C2 (ru) * 2002-09-16 2009-06-10 Глаксо Груп Лимитед ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ)
TWI283679B (en) 2002-10-22 2007-07-11 Eisai Co Ltd 7-phenylpyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
RU2387654C2 (ru) * 2004-07-27 2010-04-27 Сгкс Фармасьютиклз, Инк. Конденсированные гетероциклические модуляторы киназ
RU2389728C2 (ru) * 2004-07-27 2010-05-20 Сгкс Фармасьютиклз, Инк. Модуляторы киназы на основе производных пирролопиридина
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
RU2287273C1 (ru) * 2005-06-23 2006-11-20 Федеральное государственное образовательное учреждение высшего профессионального образования Кубанский государственный аграрный университет Применение n-замещенных 3-циано-4,6-диметил-5-хлорпиридил-2-сульфониламидов в качестве антидотов гербицида 2,4-дихлорфеноксиуксусной кислоты на подсолнечнике
RU2287275C1 (ru) * 2005-06-23 2006-11-20 Федеральное государственное образовательное учреждение высшего профессионального образования Кубанский государственный аграрный университет ПРИМЕНЕНИЕ 3[(ЗАМЕЩЕННЫЙ ФЕНИЛ) КАРБОКСАМИДО]-1,4,6-ТРИМЕТИЛ-5-R ПИРАЗОЛО [4,5-b]ПИРИДИНОВ В КАЧЕСТВЕ АНТИДОТОВ 2,4-Д
RU2287274C1 (ru) * 2005-06-23 2006-11-20 Федеральное государственное образовательное учреждение высшего профессионального образования Кубанский государственный аграрный университет ПРИМЕНЕНИЕ 3-АМИНО (ЗАМЕЩЕННЫЙ АМИНО)-1,4,6-ТРИМЕТИЛ-5-R-ПИРАЗОЛО [4,5-b] ПИРИДИНОВ В КАЧЕСТВЕ РЕГУЛЯТОРОВ РОСТА ПОДСОЛНЕЧНИКА
RS50821B (sr) * 2005-06-27 2010-08-31 Sanofi-Aventis Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
CA2647596C (en) * 2006-04-04 2012-06-12 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
RU2358973C1 (ru) * 2008-02-11 2009-06-20 Государственное научное учреждение Всероссийский научно-исследовательский институт биологической защиты растений Россельхозакадемии 3-[(3,5-ДИНИТРОФЕНИЛ)КАРБОКСАМИДО]-1,4,6-ТРИМЕТИЛ-5-ХЛОРПИРАЗОЛО[3,4-b]ПИРИДИН В КАЧЕСТВЕ АНТИДОТА 2,4-Д НА ПОДСОЛНЕЧНИКЕ
RU2357966C1 (ru) * 2008-02-12 2009-06-10 Федеральное государственное образовательное учреждение высшего профессионального образования Кубанский государственный аграрный университет N-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИЛ-3-СУЛЬФОНИЛАМИДЫ, ПРОЯВЛЯЮЩИЕ РОСТРЕГУЛИРУЮЩУЮ АКТИВНОСТЬ
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
NZ588376A (en) 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
US8791146B2 (en) 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
CA2836463A1 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2013348019A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
EP2922852A4 (en) * 2012-11-20 2016-05-25 Discoverybiomed Inc SMALL MOLECULAR CFTR CORRECTORS
TWI498325B (zh) 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
CN108558876B (zh) * 2018-05-28 2020-08-04 中南大学 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3804843A (en) * 1971-12-23 1974-04-16 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carbonitriles
DE3145287A1 (de) 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
US5082846A (en) * 1990-08-30 1992-01-21 Sandoz Ltd. Use of the R-(+)-isomer of 2-methoxy-3-octadecyloxy-propanol-(1)-phosphoric acid, monocholine ester in treating multiple sclerosis
JPH05196008A (ja) 1991-11-20 1993-08-06 Myotoku Kk 空気圧動作装置とその制御装置
WO1993010715A2 (en) 1991-12-03 1993-06-10 Vesitec Medical, Inc. Surgical treatment of stress urinary incontinence
IT222061Z2 (it) 1991-12-03 1994-12-29 Hydro Aluminium Systems Spa Complesso di profilati metallici per serramenti muniti di squadrette di rinforzo
JPH0669494B2 (ja) 1991-12-04 1994-09-07 南雄 河野 医療用窓付断熱カテーテル
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof

Also Published As

Publication number Publication date
AU2350595A (en) 1996-01-05
NZ284846A (en) 1998-12-23
ZA954679B (en) 1996-12-09
CA2192820A1 (en) 1995-12-21
IL114003A0 (en) 1995-10-31
KR100235277B1 (ko) 1999-12-15
US6248753B1 (en) 2001-06-19
FI112659B (fi) 2003-12-31
EP0765327A1 (en) 1997-04-02
FI965022A0 (fi) 1996-12-13
JP2891544B2 (ja) 1999-05-17
CZ367096A3 (en) 1997-10-15
BR9502707A (pt) 1996-06-04
CO4290424A1 (es) 1996-04-17
IL114003A (en) 1999-12-31
FI965022L (fi) 1996-12-13
AU687196B2 (en) 1998-02-19
PE13396A1 (es) 1996-04-27
CA2192820C (en) 2000-11-28
HU219911B (hu) 2001-09-28
JPH09507855A (ja) 1997-08-12
HUT75776A (en) 1997-05-28
ATE182332T1 (de) 1999-08-15
WO1995034563A1 (en) 1995-12-21
NO965378D0 (no) 1996-12-13
CN1056611C (zh) 2000-09-20
NO965378L (no) 1996-12-13
ES2135062T3 (es) 1999-10-16
TW432064B (en) 2001-05-01
NO307968B1 (no) 2000-06-26
EP0765327B1 (en) 1999-07-21
DE69510940D1 (de) 1999-08-26
RU2135498C1 (ru) 1999-08-27
MX9606504A (es) 1997-03-29
HU9603469D0 (en) 1997-02-28
DE69510940T2 (de) 1999-11-11
CZ287613B6 (en) 2001-01-17
PL317705A1 (en) 1997-04-28
CN1150803A (zh) 1997-05-28
GR3031166T3 (en) 1999-12-31
PL181895B1 (pl) 2001-10-31

Similar Documents

Publication Publication Date Title
DK0765327T3 (da) Pyrazolo- og pyrrolopyridiner
FI935585A0 (fi) Pyrrolopyrimidiner
EE200000318A (et) Uudsed ühendid
NO963239L (no) Klorpyrimid-mellomprodukter
FI952721A7 (fi) Aine maksa-sappi-sairauksien hoitamiseksi
ES2192839T3 (es) Timosina beta 4 oxidada.
IT1285770B1 (it) Composti corticoidei
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE3883966D1 (de) Behandlung durchlässiger membranen.
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
DE69114853D1 (de) Abwasserbehandlung.
NO20005548D0 (no) Mykobakterieinhibitorer
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
ATE212839T1 (de) Hämoregulatorische verbindungen
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
TR199800705T2 (da)
YU40098A (sh) Upotreba olanzapina za dobijanje leka